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Abstract 
Purpose: We aimed to evaluate the interaction between the overall severity of chronic 
rhinosinusitis (CRS) before treatment and subjective improvement following surgical or medical 
treatment. 
Procedures: A group of 97 patients with CRS completed the visual analog scale (VAS) symptom 
scores and Sino-Nasal Outcome Test 22 (SNOT-22) questionnaire at the moment of their sinus 
computerized tomography (CT) scan. Data were analyzed with two-step cluster analysis based 
on gender, polyp presence, CT scan and VAS scores for symptoms.  
Results: There were three clusters: the first cluster with 37 female patients with CRS without 
nasal polyps (CRSsNP), the second cluster formed a cohort of 30 patients with CRS and NP, 
CRSwNP (15 male and 15 female); and third cluster had 30 male patients with CRS without NP 
(CRSsNP). Different symptom patterns between clusters were identified. After adjustment for 
polyp presence, gender, eosinophilia (p = 0.021) and the SNOT-22 score (p=0.005) were found 
to be better outcome predictors than the CT score (p = 0.26).  
Conclusion: Long-term patient satisfaction is significantly associated with the subjective 
symptoms’ severity prior to treatment: postnasal drip and overall disease severity (SNOT-22 
score), but not with the objective severity of the disease (CT score and inflammation). 
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Introduction 
Chronic rhinosinusitis (CRS) is a complex syndrome which has a significant impact on health-
related quality of life (HRQL). Based on endoscopic studies, CRS is divided into two 
phenotypes: with and without nasal polyps (CRSwNP and CRSsNP, respectively). [1] Recent 
studies indicate that phenotypes and some confounders, like comorbidities and gender, play a 
major role in the definition of the pattern of CRS symptoms and HRQL impairment. [2, 3] The 
overall subjective severity of the disease may help to predict the outcomes of surgical treatment. 
[4, 5, 6, 7] The most common objective severity staging is based on CT scans, rather than on 
endoscopy scores, however, radiographic staging  does not correlate with symptoms, nor does it 
help in predicting subjective improvement after sinus surgery [8]. Objective outcome measures 
(endoscopy, CT score, eosinophilic inflammation, osteitis) correlate significantly among 
themselves. However, correlation between subjective (HRQL) and objective outcomes is often 
absent or mild. Furthermore, several papers have suggested that CRS patients with psychiatric 
distress (somatization, anxiety, depression) or those exposed to chronic psychological stress, 
report with more severe CRS symptoms and higher HRQL impairment. [9, 10] 
Several treatment options are available, but approximately 20% of patients with CRS do not 
respond well to the recommended treatment. [11] It is suggested that, besides differences in 
symptom patterns, major phenotypes differ in the response to surgical or combined (surgical and 
drug) treatment. [12] Early recognition of patients who are refractory to the long term medical 
and surgical treatment may prevent repetitive unnecessary sinus surgery and potential 
complications of such procedures. 
This study was done to evaluate the interaction between CT scores, subjective disease severity, 
based on symptom scores and HRQL impairment, and subjective improvement after drug or 
  
surgical treatment. The secondary aim was to evaluate the interaction between severity of 
inflammation, based on inflammatory cell infiltration in sinus mucosa collected at surgery, in 
patients where such samples were available for analysis, with Patient Response Rating Scale 
(PRRS) related to overall improvement after surgical treatment.  
 
Material and methods 
This prospective observational study was conducted at the Department of Otolaryngology and 
Head and Neck Surgery and at the Department of Radiology, University Hospital Centre Sestre 
milosrdnice from January 2013 to February 2016. It was approved by the Ethics Committee of 
University Hospital Centre Sestre milosrdnice, Zagreb School of Medicine, adhering to the 
Helsinki Declaration Revision of 1989. All patients who met the European Position Paper on 
Rhinosinusitis and Nasal Polyps 2012 (EPOS 2012) clinical criteria for CRS and provided 
informed consent were approved for entry into the study. [1] Symptom based diagnosis was 
confirmed by evidence of objective signs of the disease based on endoscopy and CT scans. CT 
scans were taken as a part of the preoperative procedure or as a diagnostic tool in evaluation of 
patients with CRS. Patients were excluded if they had acute exacerbation of rhinosinusitis, 
trauma or tumors of the nasal/sinus cavities, cystic fibrosis, granulomatous disease affecting the 
sinus or nasal cavity mucosa, or age <18 years. 
Demographic information such as age and gender, duration of symptoms, history of previous 
surgery, concurrent asthma, and allergy to relevant airborne allergens, medication history, was 
collected. For patients with seasonal allergic rhinitis, CT scans and questionnaires were taken at 
least 2 months after the pollen season. The extent of sinus opacification was graded according to 
the Lund-Mackay staging system. [13] Each patient was asked to fill out two questionnaires to 
  
grade their subjective symptoms. The visual analogue scale (VAS) for major and minor 
symptoms was implemented according to the recommendation by the Rhinosinusitis Task Force. 
[14] The symptoms assessed by the VAS were: nasal discharge, nasal obstruction, postnasal 
discharge, smell impairment, facial pain/pressure, facial fullness, headache, dental pain, halitosis, 
cough, ear pain/fullness and fatigue. Patients graded their subjective symptoms with VAS 
marking the intensity of the symptoms on a straight line from 0 to 10cm.  
Sino Nasal Outcome Test 22 (SNOT-22) is the most commonly used validated disease specific 
questionnaire that provides a quantitative measure of symptoms severity and health related 
quality of life for patients with CRS. Intensity of each symptom is scored on a 0-5 Likert scale, 
whereby a score of 0 signifies no symptoms and the maximum value of 5 signifies the most 
severe symptoms. [10, 11] CT scans of the paranasal sinuses were taken using a multidetector CT 
scanner with spiral mode scanning and axial cuts of 0.5 mm thickness, and afterwards evaluated 
using multiplanar reconstruction images. A standard Patient Response Rating Scale (PRRS) was 
used to classify the subjective effect of the treatment in the period of 1 to 2 years after surgery 
and/or other medical treatment. [15]  Patient rated effects of treatment from 1 to 5: 1- desperately 
worse, 2-worse, 3- no change, 4-improvement (although symptoms are present) and 5- cured (no 
symptoms present). 
After the follow-up period of 1 to 2 years, patients were evaluated through telephone surveys for 
the overall improvement after treatment, either drug or surgical treatment, using the PRRS. 
In patients with surgical samples available, the semi-quantitative scoring system was used to 
grade intensity of inflammation in sinus mucosa, for eosinophils and mononuclear cells (0- no 
eosinophils; 1= up to 10 eosinophils per high power field (HPF), 2= 10-20 eosinophils per HPF; 
3 = 20 -100 eosinophils per HPF; 4 = more than 100 eosinophils per HPF). [16] 
  
In order to define further subgroups within CRS, related to subjective and objective disease 
severity and symptoms pattern, we performed two-step cluster analysis which included two most 
important categorical characteristics: nasal polyps and gender, objective severity of disease 
(Lund-Mackay score) and VAS scores for symptoms based on major and minor symptoms (nasal 
secretion, postnasal secretion, smell impairment, nasal obstruction, facial pain/fullness, headache 
and fatigue) prior to treatment. Two step cluster analyses is an exploratory statistical tool 
designed to reveal grouping within datasets that are not otherwise apparent. It can handle 
categorical and numerical variables used in analyses in the same time. When calculating 
differences between clusters we used Chi-square test for categorical variables and Kruskal Wallis 
nonparametric statistical test for numerical variables. Significant differences between variables 
were post hoc tested with Mann Whitney U statistical test. A linear regression analysis was 
performed to determine the independent relationship between PRRS score as dependent variable 
and VAS symptom scores, SNOT-22 score and Lund-Mackay score as independent variables. In 
order to control the potential influence of major phenotype characteristics as gender and nasal 
polyp presence, these variables were included as covariates in the linear regression model. Data 
were quantified through regression coefficients separately for overall patients and for group of 
patients on medical or surgery therapy performed with a statistical significance set at a p <0.05.  
Statistical analysis was performed with Statistical Package for the Social Sciences (SPSS version 
23.0, Chicago, IL, USA). 
 
Results 
From a total of 110 CRS patients evaluated, 97 patients were subjected to two-step cluster 
analyses, as others had missing variables and were excluded from the study. The analysis 
  
detected cohort differences in CRS clustering according to gender and polyp presence, coupled 
with VAS scores for major and minor symptoms. Whereas polyp patients were in one cluster, 
regardless of gender, those without polyps separated into two distinct gender- based clusters with 
the female group having significantly more asthma and tending to be older. (Tables 1 and 2). 
Significant differences were found in comorbidities between three clusters. Asthma, allergy and 
ASA intolerance were more common in patients with nasal polyps (cluster 2). The differences 
between the three clusters for VAS symptom scores are shown in Figure 1. As VAS scores were 
used as continuous variables for two-step cluster analysis, statistical differences between clusters 
for symptoms were not calculated. Box plot distributions of Lund-Mackay scores and PRRS 
scores are shown in Figure 2. Lund-Mackay score was highest in the CRSwNP cluster. SNOT-22 
score showed no significant differences between clusters (Table 2).  
When analyzing the whole study cohort, significant difference in PRRS scores between the 3 
clusters was found (p = 0.025), but in the subgroups of patients with medical or surgical therapy 
performed, no difference was detected (Table 3). However significantly higher PRRS score was 
found in operated patients compared to those with medical management only (p = <0.001) when 
the whole cohort was considered.  
In the surgically treated CRS patients, the highest inflammatory cell infiltration was found in 
mucosal samples in cluster 2 (CRSwNP patients) with a significant difference between clusters 
(p = 0.001) for eosinophils and total inflammatory cells (Table 3).    
Independent associations of PRRS score with SNOT-22, Lund-Mackay and symptom scores are 
presented in Table 4. Lower initial SNOT-22 scores in overall patients and in patients on medical 
treatment were significantly associated with higher PRRS score (p = 0.005 and p = 0.001 
respectively) but not in patients after surgical therapy (p = 0.113).  
  
Lower postnasal secretion scores were significantly associated with higher PRRS in overall 
patients (p =0.012) and in patients treated medically (p = 0.016). 
 
Discussion 
The severity of chronic rhinosinusitis (CRS) is a result of the interaction of the debilitating 
symptoms and several confounders which have an additional impact on HRQL. [17] Two-step 
cluster analysis revealed 3 almost symmetric clusters in our cohort of CRS patients when 
clustering was done with 2 major confounders (gender and polyp presence) and the combination 
of VAS and CT scores as measures of severity. Interestingly there appear to be two different 
gender- based groups of CRSsNP patients, whereas CRSwNPs is a single group, regardless of 
gender. The cluster with CRSwNP had significantly worse obstruction, smell and SNOT-22 
scores than both other clusters.  
We found higher scores for pain and fatigue in females suffering from CRSsNP, than in the other 
two clusters, and these results were not related to CT scan scores or inflammation.  Comparing 
gender- related differences in SNOT-22 in the two CRSsNP phenotypes, clusters 1 and 3, the 
mean scores for all items were worse in female patients, except for nasal obstruction. Gender 
appears a major confounder affecting overall disease severity in this phenotype and it may be 
that the pathogenesis of CRSsNPs is different in females. The higher occurrence of asthma and 
the appearance of AERD among these subjects suggest a possible forme fruste of nasal 
polyposis, rather than a problem with immune deficiency. Male patients in the CRSsNP 
phenotype (cluster 3) also have significantly better improvement rate than female CRSsNP 
(cluster 1). On the other hand, the subjective outcomes in CRSwNP patients were not affected by 
gender. 
  
It has been demonstrated that severity of CRS in a disease specific questionnaire, such as SNOT-
22, is a good predictor of the patient’s decision for sinus surgery and for the short-term 
subjective improvement after surgical treatment for CRS. [20] Meta-analysis of 4 randomized 
trials comparing different methods of medical and surgical treatment in CRSwNP has shown no 
difference in patient reported outcomes and HRQL, however, as studies in the meta-analysis 
were of very low quality, further evidence is still  needed. [21] Although we have demonstrated a 
greater benefit of surgical treatment on our cohort, we cannot rely on this data, as the study was 
not randomized. Obviously the selection bias of our study group has demonstrated significantly 
better improvement in the surgical group and did not confirm higher values of SNOT-22 in 
patients who decided for surgery. Unfortunately, the type of phone survey did not enable us to 
recognize why patients with higher overall disease severity (high SNOT-22 score) were not 
assigned to surgery. Surgery was performed in more than 80% of the patients whose rating 
improved or were cured, while more than 70% of patients who remained unchanged or got worse 
had medical treatment only in our cohort. 
Only postnasal drip and SNOT-22 scores prior to treatment, used as a measure of overall disease 
severity, seem to affect long-term outcomes, and we may speculate from the results of the 
regression analysis that they seem to be predictors of worse outcomes. It indicates that difficult-
to-treat patients, who are unresponsive to all kinds of treatment, have the interaction of many 
factors which influence the overall CRS severity, not necessarily only related to the disease 
itself. [22]  
We have not confirmed that higher CT scores have prognostic value on poor long term 
outcomes. Higher levels of mucosal hyperplasia, defined as higher sinus CT scores, and higher 
level of eosinophilic inflammation of sinus mucosa collected at surgery, seem to result in better 
  
subjective improvement after surgery. Inflammation and CT scores are  higher in CRSwNP, (in 
patients in cluster 1) which do not seem to result in worse outcomes compared to male CRSsNP 
patients, and  are better than CRSsNP female patients.  This confirms previous findings that 
CRSwNP patients demonstrate more satisfaction with surgical outcomes and suggests that 
comparison between mixed groups of CRs patients with and without nasal polyps is unhelpful. 
[12] 
The major strength of our study is the observation of distinct clusters within CRS other than 
those previously recognized and the observation that gender- related differences are important in 
CRSsNPs, but not in CRS wNPs. 
 
Conclusion 
Long-term patient satisfaction, with medical or surgical treatment, is significantly associated 
with the subjective symptoms’ severity prior to treatment: postnasal drip and overall disease 
severity (SNOT-22 score), but not with the objective severity of the disease (CT score and 
inflammation). 
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Table captions 
Table 1. Assignment of patients to clusters according to CRS phenotype and gender expressed as 
patients number per cluser (percentage). 
Table 2. Demographic data and distribution of comorbidities among cluster groups, presented as 
medians (minimum - maximum) or percentages. 
Table 3. Patients demographics, severity of inflammation and patient reporting outcomes among 
cluster groups depending on treatment modality 
Table 4. Independent association between PRRS score and SNOT-22 score, LM score, symptom 
scores and cell infiltration before and after surgical or medical management 
 
Figure legends 
Fig. 1 VAS symptom scores presented as mean ± standard error for each cluster. 
Fig. 2 Lund-Mackay (LM) scores and Patient Response Rating Scale (PRRS) scores per cluster 
presented as box-plots. 
 
  
  
 
 
  
  
 
 
 
 
 
 
Tables and Legends 
 
Table 1. Assignment of patients to clusters according to CRS phenotype and gender expressed 
as patients number(percentage) per cluster.   
  Cluster 1 Cluster 2 Cluster 3 
Gender 
Male N (%) 0  (0) 15  (33.3) 30  (66.7) 
Female N (%) 37  (71.2) 15  (33.3) 0  (0) 
Clinical 
phenotype 
CRSsNP N 
(%) 
37  (71.2) 0   (0) 30  (66.7) 
CRSwNP N 
(%) 
0  (0) 30  (66.7) 0  (0) 
Patients Total N = 97 37 30 30 
CRSsNP Chronic rhinosinusitits without nasal polps, CRSwNP Chronic rhinosinusits with 
nasal polyps, N number of patients 
 
 
Table 2. Demographic data and distribution of comorbidities among cluster groups, presented 
as medians (minimum - maximum) or percentages. 
Variable Cluster 1 Cluster 2 Cluster 3 P value 
Age (years) 53.5 (40-62) 52.0 (26-70) 41.0 (19-68) 0.102 
Symptom duration (years) 5 (0-40) 10 (0-30) 5 (1-15) 0.323 
Asthma N (%) 9 (25.0) 14 (46.7) 3 (10.0)  0.006* 
Allergy   N (%) 12 (33.3) 17 (56.7) 8 (26.7) 0.042* 
ASA intolerance N (%) 2 (5.7) 5 (17.2) 0 (0.0) 0.049* 
Objective and subjective disease severity measures 
Lund-Mackay score 8.5 (5-15) 15.5 (9-24) 7 (1-15) <0.001* 
SNOT 22 (before 
treatment) 
50,5 (23-67) 52,0 (26-70) 41,0 (19-68) 0.067 
PRRS       (after treatment) 4.0 (3-5) 4.0 (2-5) 4 (3-5)  0.025* 
ASA hypersensitivity to acetyl salicylic acid, SNOT-22 Sinonasal Outcome test 22, PRRS 
Patient Response Rating Scale, N number of patients 
*P value of  <0.05 was considered statistically significant 
 
Table 3. Patients demographics, severity of inflammation and patient reporting outcomes 
among cluster groups depending on treatment modality 
Surgical therapy 
 Cluster 1 Cluster 2 Cluster 3 P  value 
Patients N (%) 16 (43.2) 26 (86.7) 18 (60)  
Mononuclear 
cells  
2.0 (1.0-2.5) 3.0 (1.0-4.0) 1.8 (1.0-3.5) 0.064 
Eosinophil cells 1.0 (1.0-2.0) 3.0 (1.0-4.0) 1.5 (0.5-3.5)   0.001* 
Mononuclear + 
eosinophil cells 
3.0 (3.0-3.5) 5.5 (2.0-8.0) 4.0 (2.0-7.0)   0.001* 
PRRS 4 (1-5) 4 (2-5) 4 (2-5) 0.270 
Medical therapy 
Patients N (%) 21 (56.8) 4 (13.3) 12 (40)  
PRRS 3 (1-5) 2.5(1-3) 3.5 (1-4) 0.165 
PRRS Patient Response Rating Scale,  N number of patients 
*P value of  <0.05 was considered statistically significant 
 
Table 4. Independent association between PRRS score and SNOT-22 score, LM score, 
symptom scores and cell infiltration related to surgical or medical management 
 Estimate (95% CI) P-value 
Regression of SNOT 22 score vs. PRRS score   
Overall 
-0.018 (-0.030, -
0.006) 
0.005* 
In patients with surgery 
-0.012  (-0.026, 
0.003) 
0.113 
In patients without surgery   
-0.027 (-0.042, -
0.012) 
0.001* 
Regression of LM score vs. PRRS score   
Overall 
 0.028 (-0.021, 
0.077) 
0.255 
In patients with surgery 
 0.020 (-0.029, 
0.069) 
0.428 
In patients without surgery   
-0.026 (-0.114, 
0.063) 
0.558 
Regression of nasal secretion vs. PRRS score   
Overall 0.014 (-0.055, 0.083) 0.690 
In patients with surgery 
 0.049 (-0.023, 
0.121) 
0.178 
In patients without surgery   
-0.103 (-0.202, -
0.003) 
0.043* 
Regression of nasal obstruction vs. PRRS score   
Overall -0.018 (0.092, 0.057) 0.638 
In patients with surgery -0.057 (-0.153, 0.039 0.237 
In patients without surgery   
-0.064 (-0.156, 
0.027) 
0.165 
Regression of smell impairment vs. PRRS score   
Overall 
 0.029 (-0.038, 
0.095) 
0.392 
In patients with surgery 
 0.003 (-0.076, 
0.086) 
0.935 
In patients without surgery   
-0.018 (-0.107, 
0.071) 
0.686 
Regression of postnasal secretion vs PRRS score   
Overall 
-0.083 (-0.148, -
0.019) 
0.012* 
In patients with surgery 
-0.059 (-0.013, 
0.011) 
0.096 
In patients without surgery 
-0.113 (-0.204, -
0.022) 
0.016* 
Regression of facial pan/fulness  vs. PRRS score   
Overall 
-0.028 (-0.094, 
0.038) 
0.409 
In patients with surgery 
-0.069 (-0.138, -
0.001) 
0.047* 
In patients without surgery 
-0.037 (-0.138, 
0.003) 
0.458 
Regression of headache vs. PRRS score   
Overall 
-0.045 (-0.110, 
0.020) 
0.173 
In patients with surgery 
-0.044 (-0.114, 
0.026) 
0.218 
In patients without surgery 
-0.072 (-0.165, 
0.021) 
0.126 
Regression of fatigue vs. PRRS score   
Overall 
-0.052 (-0.131, 
0.028) 
0.202 
In patients with surgery 
-0.062 (-0.152, 
0.028) 
0.172 
In patients without surgery 
-0.046 (-0.157, 
0.054) 
0.403 
Regression of cell infilitration vs PRRS score in 
patients with surgery 
  
Monoculear cells vs PRRS score 0.157 (-0.151, 0.466) 0.310 
Eosinophil cells vs PRRS score 0.310 (0.010, 0.611) 0.043* 
Mononuclear + eosinophil cells vs PRRS score 0.142 (-0.018, 0.303) 0.081 
PRRS Patient Response Rating Scale, SNOT 22 Sinonasal Outcome test 22, LM Lund-Mackay 
score 
*P value of  <0.05 was considered statistically significant- better to use <0.025 because of 
multiple comparisons 
 
Table 1. Assignment of patients to clusters according to CRS phenotype and gender expressed 
as patients number(percentage) per cluster.   
  Cluster 1 Cluster 2 Cluster 3 
Gender 
Male N (%) 0  (0) 15  (33.3) 30  (66.7) 
Female N (%) 37  (71.2) 15  (33.3) 0  (0) 
Clinical 
phenotype 
CRSsNP N 
(%) 
37  (71.2) 0   (0) 30  (66.7) 
CRSwNP N 
(%) 
0  (0) 30  (66.7) 0  (0) 
Patients Total N = 97 37 30 30 
CRSsNP Chronic rhinosinusitits without nasal polps, CRSwNP Chronic rhinosinusits with 
nasal polyps, N number of patients 
 
Table 2. Demographic data and distribution of comorbidities among cluster groups, presented 
as medians (minimum - maximum) or percentages. 
Variable Cluster 1 Cluster 2 Cluster 3 P value 
Age (years) 53.5 (40-62) 52.0 (26-70) 41.0 (19-68) 0.102 
Symptom duration (years) 5 (0-40) 10 (0-30) 5 (1-15) 0.323 
Asthma N (%) 9 (25.0) 14 (46.7) 3 (10.0)  0.006* 
Allergy   N (%) 12 (33.3) 17 (56.7) 8 (26.7) 0.042* 
ASA intolerance N (%) 2 (5.7) 5 (17.2) 0 (0.0) 0.049* 
Objective and subjective disease severity measures 
Lund-Mackay score 8.5 (5-15) 15.5 (9-24) 7 (1-15) <0.001* 
SNOT 22 (before 
treatment) 
50,5 (23-67) 52,0 (26-70) 41,0 (19-68) 0.067 
PRRS       (after treatment) 4.0 (3-5) 4.0 (2-5) 4 (3-5)  0.025* 
ASA hypersensitivity to acetyl salicylic acid, SNOT-22 Sinonasal Outcome test 22, PRRS 
Patient Response Rating Scale, N number of patients 
*P value of  <0.05 was considered statistically significant 
 
Table 3. Patients demographics, severity of inflammation and patient reporting outcomes 
among cluster groups depending on treatment modality 
Surgical therapy 
 Cluster 1 Cluster 2 Cluster 3 P  value 
Patients N (%) 16 (43.2) 26 (86.7) 18 (60)  
Mononuclear 
cells  
2.0 (1.0-2.5) 3.0 (1.0-4.0) 1.8 (1.0-3.5) 0.064 
Eosinophil cells 1.0 (1.0-2.0) 3.0 (1.0-4.0) 1.5 (0.5-3.5)   0.001* 
Mononuclear + 
eosinophil cells 
3.0 (3.0-3.5) 5.5 (2.0-8.0) 4.0 (2.0-7.0)   0.001* 
PRRS 4 (1-5) 4 (2-5) 4 (2-5) 0.270 
Medical therapy 
Patients N (%) 21 (56.8) 4 (13.3) 12 (40)  
PRRS 3 (1-5) 2.5(1-3) 3.5 (1-4) 0.165 
PRRS Patient Response Rating Scale,  N number of patients 
*P value of  <0.05 was considered statistically significant 
 
Table 4. Independent association between PRRS score and SNOT-22 score, LM score, 
symptom scores and cell infiltration related to surgical or medical management 
 Estimate (95% CI) P-value 
Regression of SNOT 22 score vs. PRRS score   
Overall 
-0.018 (-0.030, -
0.006) 
0.005* 
In patients with surgery 
-0.012  (-0.026, 
0.003) 
0.113 
In patients without surgery   
-0.027 (-0.042, -
0.012) 
0.001* 
Regression of LM score vs. PRRS score   
Overall 
 0.028 (-0.021, 
0.077) 
0.255 
In patients with surgery 
 0.020 (-0.029, 
0.069) 
0.428 
In patients without surgery   
-0.026 (-0.114, 
0.063) 
0.558 
Regression of nasal secretion vs. PRRS score   
Overall 0.014 (-0.055, 0.083) 0.690 
In patients with surgery 
 0.049 (-0.023, 
0.121) 
0.178 
In patients without surgery   
-0.103 (-0.202, -
0.003) 
0.043* 
Regression of nasal obstruction vs. PRRS score   
Overall -0.018 (0.092, 0.057) 0.638 
In patients with surgery -0.057 (-0.153, 0.039 0.237 
In patients without surgery   
-0.064 (-0.156, 
0.027) 
0.165 
Regression of smell impairment vs. PRRS score   
Overall 
 0.029 (-0.038, 
0.095) 
0.392 
In patients with surgery 
 0.003 (-0.076, 
0.086) 
0.935 
In patients without surgery   
-0.018 (-0.107, 
0.071) 
0.686 
Regression of postnasal secretion vs PRRS score   
Overall 
-0.083 (-0.148, -
0.019) 
0.012* 
In patients with surgery 
-0.059 (-0.013, 
0.011) 
0.096 
In patients without surgery 
-0.113 (-0.204, -
0.022) 
0.016* 
Regression of facial pan/fulness  vs. PRRS score   
Overall 
-0.028 (-0.094, 
0.038) 
0.409 
In patients with surgery 
-0.069 (-0.138, -
0.001) 
0.047* 
In patients without surgery 
-0.037 (-0.138, 
0.003) 
0.458 
Regression of headache vs. PRRS score   
Overall 
-0.045 (-0.110, 
0.020) 
0.173 
In patients with surgery 
-0.044 (-0.114, 
0.026) 
0.218 
In patients without surgery 
-0.072 (-0.165, 
0.021) 
0.126 
Regression of fatigue vs. PRRS score   
Overall 
-0.052 (-0.131, 
0.028) 
0.202 
In patients with surgery 
-0.062 (-0.152, 
0.028) 
0.172 
In patients without surgery 
-0.046 (-0.157, 
0.054) 
0.403 
Regression of cell infilitration vs PRRS score in 
patients with surgery 
  
Monoculear cells vs PRRS score 0.157 (-0.151, 0.466) 0.310 
Eosinophil cells vs PRRS score 0.310 (0.010, 0.611) 0.043* 
Mononuclear + eosinophil cells vs PRRS score 0.142 (-0.018, 0.303) 0.081 
PRRS Patient Response Rating Scale, SNOT 22 Sinonasal Outcome test 22, LM Lund-Mackay 
score 
*P value of  <0.05 was considered statistically significant- better to use <0.025 because of 
multiple comparisons 
